[go: up one dir, main page]

MX2016003650A - Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica. - Google Patents

Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica.

Info

Publication number
MX2016003650A
MX2016003650A MX2016003650A MX2016003650A MX2016003650A MX 2016003650 A MX2016003650 A MX 2016003650A MX 2016003650 A MX2016003650 A MX 2016003650A MX 2016003650 A MX2016003650 A MX 2016003650A MX 2016003650 A MX2016003650 A MX 2016003650A
Authority
MX
Mexico
Prior art keywords
treat
f2alfa
prostaglandina
attract
analogs
Prior art date
Application number
MX2016003650A
Other languages
English (en)
Other versions
MX374476B (es
Inventor
Warren J Scherer
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of MX2016003650A publication Critical patent/MX2016003650A/es
Publication of MX374476B publication Critical patent/MX374476B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • External Artificial Organs (AREA)

Abstract

Se reclama un método para tratar la cicatrización cutánea atrófica. El método involucra la aplicación tópica de una cantidad terapéutica de prostaglandina F2-alfa (PGF 2a) o un análogo de PGF 2a directamente al área de la cicatrización atrófica.
MX2016003650A 2013-09-26 2014-09-26 Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica. MX374476B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (2)

Publication Number Publication Date
MX2016003650A true MX2016003650A (es) 2016-06-24
MX374476B MX374476B (es) 2025-03-06

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003650A MX374476B (es) 2013-09-26 2014-09-26 Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica.

Country Status (11)

Country Link
US (1) US10039770B2 (es)
EP (1) EP3049088B1 (es)
JP (1) JP6453318B2 (es)
KR (1) KR102221499B1 (es)
CN (1) CN105658221B (es)
AU (1) AU2014326298B2 (es)
BR (1) BR112016006426A2 (es)
CA (1) CA2924460A1 (es)
MX (1) MX374476B (es)
RU (1) RU2690183C2 (es)
WO (1) WO2015044788A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319607A4 (en) * 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
CN102026656A (zh) * 2008-05-16 2011-04-20 科尔泰拉公司 促进伤口愈合的方法
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
CA2819859A1 (en) * 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CN103747775A (zh) * 2011-01-31 2014-04-23 阿勒根公司 促进毛发生长的方法
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
US9051294B2 (en) * 2013-04-30 2015-06-09 Allergan, Inc. Therapeutic agents

Also Published As

Publication number Publication date
KR102221499B1 (ko) 2021-03-02
CN105658221A (zh) 2016-06-08
US10039770B2 (en) 2018-08-07
EP3049088A1 (en) 2016-08-03
AU2014326298B2 (en) 2019-07-04
EP3049088B1 (en) 2021-02-17
AU2014326298A1 (en) 2016-04-07
MX374476B (es) 2025-03-06
RU2016110925A3 (es) 2018-07-13
US20160228453A1 (en) 2016-08-11
CA2924460A1 (en) 2015-04-02
KR20160055941A (ko) 2016-05-18
RU2690183C2 (ru) 2019-05-31
WO2015044788A1 (en) 2015-04-02
BR112016006426A2 (pt) 2017-08-01
JP6453318B2 (ja) 2019-01-16
CN105658221B (zh) 2022-05-10
JP2016531872A (ja) 2016-10-13
RU2016110925A (ru) 2017-11-01

Similar Documents

Publication Publication Date Title
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
CR20150020A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
GT201300009A (es) Derivados de tetrahidro-pirido-pirimidina
HN2010001920A (es) Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa
AR076110A1 (es) Un electrodo de rf para dispositivos esteticos y de moldeado corporal y metodo para utilizar el mismo
BR102014006335B8 (pt) Método para produzir uma população isolada de células-tronco de polpa dentária imaturas (idpscs) e uso
CL2012003624A1 (es) Uso estético de acido cicórico y sus derivados para regular la pigmentacion de la piel; kit para tratar y/o prevenir trastornos de pigmentacion de la piel y/o imperfecciones de la piel.
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
EA201201296A1 (ru) Способы лечения диабетических язв стопы
EA201591996A1 (ru) Способы и композиции для заживления раны
MX2015008997A (es) Moleculas pequeñas que promueven la regeneracion de la piel.
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
MX2016003650A (es) Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica.
AR088233A1 (es) Composicion para utilizar en la mejora de la salud de las uñas en un paciente humano
EA201591185A1 (ru) Применение пидотимода для лечения псориаза
CL2016000338A1 (es) Composición de cuidado bucal
MX2016009167A (es) Metodo de tratamiento basado en combinacion.
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
CY1119117T1 (el) Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση
CL2017000915A1 (es) Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosis
EA201690551A1 (ru) Применение гидроксипропил хитозана для лечения онихомикоза
RU2013112392A (ru) Способ лечения заболеваний пародонта
EA201400399A1 (ru) Композиция для нанесения на кожу и ее применение
UA76330U (uk) Спосіб лікування запальних процесів

Legal Events

Date Code Title Description
FG Grant or registration